NasdaqGM:PTI

Stock Analysis Report

Executive Summary

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of various small molecule therapeutics to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Proteostasis Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PTI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-16.1%

PTI

-4.2%

US Biotechs

-7.4%

US Market


1 Year Return

-59.5%

PTI

6.5%

US Biotechs

10.5%

US Market

Return vs Industry: PTI underperformed the US Biotechs industry which returned 6.5% over the past year.

Return vs Market: PTI underperformed the US Market which returned 10.5% over the past year.


Shareholder returns

PTIIndustryMarket
7 Day-16.1%-4.2%-7.4%
30 Day-5.1%1.9%-3.6%
90 Day-31.6%0.9%-0.6%
1 Year-59.5%-59.5%7.4%6.5%12.8%10.5%
3 Year-88.0%-88.0%15.8%12.7%37.4%28.6%
5 Yearn/a-1.3%-5.9%61.3%43.6%

Price Volatility Vs. Market

How volatile is Proteostasis Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Proteostasis Therapeutics undervalued compared to its fair value and its price relative to the market?

1.22x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PTI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PTI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PTI is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PTI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PTI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PTI is good value based on its PB Ratio (1.3x) compared to the US Biotechs industry average (3x).


Next Steps

Future Growth

How is Proteostasis Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

31.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PTI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PTI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PTI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PTI's revenue (68% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: PTI's revenue (68% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PTI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Proteostasis Therapeutics performed over the past 5 years?

-21.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PTI is currently unprofitable.

Growing Profit Margin: PTI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PTI is unprofitable, and losses have increased over the past 5 years at a rate of -21.8% per year.

Accelerating Growth: Unable to compare PTI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).


Return on Equity

High ROE: PTI has a negative Return on Equity (-91.51%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Proteostasis Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: PTI's short term assets ($79.7M) exceed its short term liabilities ($11.6M).

Long Term Liabilities: PTI's short term assets ($79.7M) exceed its long term liabilities ($12.3M).


Debt to Equity History and Analysis

Debt Level: PTI is debt free.

Reducing Debt: PTI currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: PTI has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if PTI's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PTI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PTI has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of -27.6% each year.


Next Steps

Dividend

What is Proteostasis Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.9%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate PTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PTI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PTI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PTI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Meenu Chhabra (47yo)

5.8yrs

Tenure

US$1,289,270

Compensation

Ms. Meenu Chhabra has been the Chief Executive Officer and President at Proteostasis Therapeutics, Inc. since May, 2014. Ms. Chhabra's initial focus is driving the development of Proteostasis' cystic fibro ...


CEO Compensation Analysis

Compensation vs Market: Meenu's total compensation ($USD1.29M) is above average for companies of similar size in the US market ($USD524.26K).

Compensation vs Earnings: Meenu's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Meenu Chhabra
President5.8yrsUS$1.29m0.16% $134.6k
Benito Munoz
Chief Scientific Officer2.9yrsUS$646.68k0.030% $25.8k
Po-Shun Lee
Consultant4.8yrsUS$647.77k0.036% $30.8k
Eric Larson
Principal Financial Officer & Principal Accounting Officer0.8yrsno datano data
Sheila Wilson
Chief Operating Officer1yrsno data0.036% $31.0k
Geoffrey Gilmartin
Chief Medical Officer1yrsno data0.029% $24.9k
Marija Zecevic
Chief Commercial Officer1yrsno data0.044% $37.3k
Sandra Zimmerman
Consultant0.8yrsno datano data
Claudia Styslinger
Investor Relations Executive0yrsno datano data

1.0yrs

Average Tenure

50yo

Average Age

Experienced Management: PTI's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Meenu Chhabra
President5.8yrsUS$1.29m0.16% $134.6k
David Arkowitz
Director0.9yrsno datano data
Franklin Berger
Chairman1.1yrsUS$82.66k0.52% $444.5k
F. Hartl
Chairman of Scientific Advisory Board0yrsno datano data
Richard Morimoto
Member of Scientific Advisory Board0yrsno datano data
Kimberlee Drapkin
Director1yrsno datano data
Daniel Finley
Member of Scientific Advisory Board0yrsno datano data
Jeffery Kelly
Director & Member of Scientific Advisory Board0yrsUS$126.16k0.20% $171.0k
Randall King
Member of Scientific Advisory Board0yrsno datano data
Richard Moss
Chairman of Clinical Advisory Board0yrsno datano data

1.0yrs

Average Tenure

58yo

Average Age

Experienced Board: PTI's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49.6%.


Top Shareholders

Company Information

Proteostasis Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Proteostasis Therapeutics, Inc.
  • Ticker: PTI
  • Exchange: NasdaqGM
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$85.385m
  • Shares outstanding: 51.13m
  • Website: https://www.proteostasis.com

Number of Employees


Location

  • Proteostasis Therapeutics, Inc.
  • 80 Guest Street
  • Suite 500
  • Boston
  • Massachusetts
  • 2135
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PTINasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDFeb 2016
42PDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2016

Biography

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of various small molecule therapeutics to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing. The company’s lead product candidates for the treatment of CF include PTI-801, a third generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/27 01:19
End of Day Share Price2020/02/26 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.